Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: rubiustx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/13/2022 | Buy → Neutral | Guggenheim | |
| 2/25/2022 | $14.00 → $5.00 | Market Perform | SVB Leerink |
| 11/9/2021 | $20.00 → $14.00 | Market Perform | SVB Leerink |
| 10/19/2021 | $25.00 → $22.00 | Equal-Weight | Morgan Stanley |
15-12G - Rubius Therapeutics, Inc. (0001709401) (Filer)
8-K - Rubius Therapeutics, Inc. (0001709401) (Filer)
25 - Rubius Therapeutics, Inc. (0001709401) (Filer)
DEF 14A - Rubius Therapeutics, Inc. (0001709401) (Filer)
PRER14A - Rubius Therapeutics, Inc. (0001709401) (Filer)
PRE 14A - Rubius Therapeutics, Inc. (0001709401) (Filer)
10-K - Rubius Therapeutics, Inc. (0001709401) (Filer)
S-8 POS - Rubius Therapeutics, Inc. (0001709401) (Filer)
S-8 POS - Rubius Therapeutics, Inc. (0001709401) (Filer)
S-8 POS - Rubius Therapeutics, Inc. (0001709401) (Filer)
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeuti
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results on Tuesday, May 10, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™.
Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or Dose-Limiting Toxicities as of the Cutoff Date Expanding Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer and Renal Cell Carcinoma Management to Host Conference Call Today at 1:15 p.m. EDT to Discuss Clinical Data and Clinical Development Next Steps for RTX-240 CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create
CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report fourth quarter and full year 2021 financial results on Friday, February 25, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report third quarter financial results on Monday, November 8, 2021, after market close. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Monday, August 9, 2021, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™.
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
3 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
Guggenheim downgraded Rubius Therapeutics from Buy to Neutral
SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $5.00 from $14.00 previously
SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $14.00 from $20.00 previously
Morgan Stanley resumed coverage of Rubius Therapeutics with a rating of Equal-Weight and set a new price target of $22.00 from $25.00 previously
Morgan Stanley reiterated coverage of Rubius Therapeutics with a rating of Equal-Weight and set a new price target of $25.00 from $24.00 previously
Morgan Stanley reiterated coverage of Rubius Therapeutics with a rating of Equal-Weight and set a new price target of $24.00 from $10.00 previously
SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $20.00 from $4.00 previously
HC Wainwright & Co. reiterated coverage of Rubius Therapeutics with a rating of Buy and set a new price target of $40.00 from $28.00 previously
SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $4.00 from $5.00 previously
SVB Leerink resumed coverage of Rubius Therapeutics with a rating of Market Perform
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)
SC 13G - Rubius Therapeutics, Inc. (0001709401) (Subject)
Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of
Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform. www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. Ltd. and Hanwha Impact Partners. The proceeds of the financing will be used to grow Cellarity's talent base, strengthen its platform, and advance its pipeline toward the clinic. "We welcome our new investors and appreciate the continued support of our current investors," said Fabrice Chouraqui, PharmD, CEO of Cellarit
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT. A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event. About Rubius Therapeutic
Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid Tumors Investor Teleconference and Webcast Scheduled Today at 7:30 a.m. EDT CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to restructure the Company and align re
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT. Investor Teleconference & Webcast An audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website and can be directly ac
The dataset will be publicly available for a Kaggle competition presented at NeurIPS 2022 hosted by Open Problems in Single-Cell Analysis in collaboration with Chan Zuckerberg Initiative, Chan Zuckerberg Biohub, Yale University, and Helmholtz Munich Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping multimodal genetic information across cell states and over time. This dataset will be used to power a competition hosted by Open Problems in Single-Cell Analysis. Cells are among the most complex and dynamic systems and are regulated by the
CAMBRIDGE, Mass., Aug. 16, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the completion of a $123 million Series C financing, bringing its total funding raised to date to $266 million. Flagship Pioneering, which founded Senda, participated along with new investors, including the Samsung Life Science Fund, Qatar Investment Authority (QIA), Bluwave Capital, and Stage 1 Ventures. Also participating in the financing are current investors, including Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Partners Investment, and State of Michigan Retirement System.
New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H'22 from Phase 1 Arm of RTX-240 + Pembrolizumab in Advanced Solid Tumors and Expansion Cohorts in Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Dose Escalation Continues in Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date; Initial Clinical Results Expected by Year-End or During 1Q'23 CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeuti
Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of
Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform. www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo
BOSTON, July 19, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose "Pepe" Carmona to its Board of Directors. Mr. Carmona brings over 20 years of leadership experience in the biopharmaceutical industry across a range of roles and therapeutic areas. "We are thrilled to welcome Pepe to our Board of Directors," said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Thera
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Susanne Schaffert, Ph.D., to its board of directors. Dr. Schaffert brings more than 25 years of experience across clinical development, marketing and sales, finance and commercialization in the global pharmaceutical and biotechnology industries, with a focus on oncology, immuno-oncology and cell therapy. Dr. Schaffert most recently served
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Noubar Afeyan, Ph.D., co-founder and member of the board of directors of Rubius Therapeutics and chief executive officer of Flagship Pioneering, as chairman of its board of directors. David Epstein who has served as chairman since 2017 will remain a member of the board. "Since we founded Rubius Therapeutics in FlagshipLabs in 2014, my conv
Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities. Werner most recently served as Wo
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h
CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology. Dr. Milstein most recently served as the Vice President of platform biology at Korro Bio, Inc., and previously led the RNAi Lead Development group at Alnylam Pharmaceuticals, Inc. Dr. Milstein will be responsible for advancing Senda's platform and scaling the Company's efforts to unlock a new class of fully programmable medicines.
CAMBRIDGE, Mass., Jan. 25, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Tom DiLenge has joined the company in a newly created role as Senior Partner, Global Public Policy, Regulatory & Governmental Strategy. In this role, DiLenge will lead and develop Flagship's public policy, regulatory, and government affairs functions to advance Flagship's priorities at the federal, state, and global levels. In addition, he will serve as an in-house advisor and expert resource to Flagship's ecosystem companies. Tom brings to Flagship Pi
On Monday, 36 companies set new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Sirius XM Holdings (NASDAQ:SIRI). The smallest company by market cap to set a new 52-week low was Altamira Therapeutics (NASDAQ:CYTO). China Pharma Holding (AMEX:CPHI) saw the most significant move of the companies, as shares traded down 871.52% to reach its new 52-week low. VEON (NASDAQ:VEON) shares rebounded the highest, with shares trading up 0.0%, bouncing back after reaching its new 52-week low. Stocks dropping to new 52-week lows on Monday: Sirius XM Holdings (NASDAQ:SIRI) shares fell to $4.20 on Monday, setting a new 5
Gainers Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb. BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares jumped 59.5% to $17.34 after the company announced positive data for its phase 2 study of Infigratinib in Achondroplasia. Avalon GloboCare Corp. (NASDAQ:ALBT) shares gained 53.5% to $3.3330. Azul S.A. (NYSE:AZUL) gained 45.3% to $6.05 after the company announced a deal to reduce the immediate cash it must expend for leased property. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) rose 28.3% to $21.49. HC Wainwright & Co. maintained Kala Pharmac
Gainers Unicycive Therapeutics (NASDAQ:UNCY) stock moved upwards by 151.2% to $1.23 during Monday's regular session. Trading volume for this security as of 12:30 EST is 77.1 million, which is 22303.6% of its average full-day volume over the last 100 days. The company's market cap stands at $18.5 million. Bellerophon Therapeutics (NASDAQ:BLPH) stock increased by 82.49% to $3.3. Bellerophon Therapeutics's stock is trading at a volume of 11.1 million shares as of 12:30 EST. This is 1023.2% of its average full-day volume over the last 100 days. The company's market cap stands at $31.4 million. BridgeBio Pharma (NASDAQ:BBIO) stock rose 58.0% to $17.18. Trading volume for BridgeBio Pharma's sto
Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares increased by 114.3% to $1.05 during Monday's pre-market session. The company's market cap stands at $15.8 million. BridgeBio Pharma (NASDAQ:BBIO) stock moved upwards by 56.39% to $17.0. The market value of their outstanding shares is at $2.5 billion. vTv Therapeutics (NASDAQ:VTVT) stock increased by 48.51% to $1.2. The company's market cap stands at $97.7 million. Kala Pharmaceuticals (NASDAQ:KALA) shares increased by 27.46% to $21.35. The company's market cap stands at $39.9 million. The company's, Q4 earnings came out yesterday. TCR2 Therapeutics (NASDAQ:TCRR) shares rose 25.61% to $1.52. The market value of their outstanding shares
Gainers Secoo Holding Limited (NASDAQ:SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday. Entera Bio Ltd. (NASDAQ:ENTX) rose 43.1% to $1.46 in pre-market trading after dropping 5% on Friday. Entera Bio recently announced the FDA's acceptance of a Type D meeting review to affirm design of the pivotal, Phase 3 protocol for EB613 PTH mini tablets, as the first oral osteoanabolic treatment of post-menopausal osteoporosis. BuzzFeed, Inc. (NASDAQ:BZFD) rose 20.7% to $1.87 in pre-market trading. BuzzFeed is expected to release its Q4 financial results on Monday, March 13, 2023, after the closing bell. BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) rose 12.5% to $2.8
Gainers ObsEva SA (NASDAQ:OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares jumped 52.7% to $3.59 after the company said data from a recent peer-reviewed clinical study demonstrated Bentrio's superior nasal residence time and rheological properties. Lavoro Limited (NASDAQ:LVRO) gained 44.7% to $13.86. Lavoro and TPB Acquisition Corporation I announced completion of business combination. HUB Cyber Security (Israel) Ltd. (NASDAQ:HUBC) rose 36.6% to $1.71 after dipping 21% on Thursday. Seer, Inc. (NASDAQ:SEER) gained 35% to $5.68 a
Gainers ObsEva SA (NASDAQ:OBSV) rose 93.1% to $0.2047 in pre-market trading after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) rose 53.1% to $4.18 in pre-market trading. Bullfrog AI recently priced its IPO at $6.50 per share. Rubius Therapeutics, Inc. (NASDAQ:RUBY) rose 28.7% to $0.1461 in pre-market trading. Rubius Therapeutics recently outlined dissolution plan, after unsuccessful attempt on alternatives. Smart for Life, Inc. (NASDAQ:SMFL) rose 19.7% to $0.2278 in pre-market trading. Smart for Life is scheduled to hold shareholder meeting on March 15, 2023. HUB Cyb
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 47.6% to $4.03 during Friday's pre-market session. The company's market cap stands at $22.7 million. Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 31.71% to $0.15. The company's market cap stands at $13.5 million. Ardelyx (NASDAQ:ARDX) shares rose 17.3% to $3.39. The market value of their outstanding shares is at $673.1 million. The company's, Q4 earnings came out yesterday. Akari Therapeutics (NASDAQ:AKTX) shares rose 16.24% to $0.38. The market value of their outstanding shares is at $28.2 million. Milestone Scientific (AMEX:MLSS) shares rose 13.92% to $0.9. The company's market cap stands at $62.8 million. Confor
Gainers Reata Pharmaceuticals (NASDAQ:RETA) stock moved upwards by 178.0% to $86.65 during Wednesday's regular session. The current volume of 10.1 million shares is 1012.6% of Reata Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $3.1 billion. OncoSec Medical (NASDAQ:ONCS) stock moved upwards by 92.59% to $2.08. Trading volume for this security as of 12:30 EST is 58.4 million, which is 7655.3% of its average full-day volume over the last 100 days. The company's market cap stands at $6.1 million. BiomX (AMEX:PHGE) stock increased by 48.84% to $0.6. Trading volume for BiomX's stock is 1.7 millio
Gainers Lucira Health, Inc. (NASDAQ:LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test. ContraFect Corporation (NASDAQ:CFRX) shares jumped 66% to $5.14. ObsEva SA (NASDAQ:OBSV) jumped 56.5% to $0.1299. ObsEva shares dropped over 50% on Friday after the company announced strategic reorganization to consolidate operations in Switzerland. Blackboxstocks Inc. (NASDAQ:BLBX) rose 33% to $0.7300. Blackboxstocks said it sees Q4 revenue of $950K-$1.05M. Moolec Science SA (NASDAQ:MLEC) gained 25.3% to $5.14. AERWINS Technologies Inc. (NASDAQ:AWIN) shares rose 24.5% to $2.0909 after gaining more than 10% on Friday. Fisker